(Q24202108)

7

0 references

Roberto D'Amico

4

0 references

Cinzia Del Giovane

2

0 references

Carlo Di Pietrantonj

5

0 references

Deirdre Beecher

6

0 references

author name string

Laura Vacchi

Cochrane Database of Systematic Reviews

3

0 references

publication date

6 June 2013

0 references

published in

0 references

cites work

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Corticosteroids for the long-term treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Effects of donepezil on memory and cognition in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Daclizumab for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Occupational therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Carnitine for fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Azathioprine for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Corticosteroids for the long-term treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Network meta-analysis models to account for variability in treatment definitions: application to dose effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Mechanism of action of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Literature systematic review on the ophthalmological side effects of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Intravenous immunoglobulins for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Methotrexate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Borrowing strength from external trials in a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Cyclophosphamide for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Therapy with glatiramer acetate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta for secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Mitoxantrone for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Multiple sclerosis: Geoepidemiology, genetics and the environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Corticosteroids treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Natalizumab for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta for primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Evaluation of networks of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Bayesian measures of model complexity and fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Network analysis of randomized controlled trials in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

MRI as an outcome in multiple sclerosis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

A double blind study on azathioprine efficacy in multiple sclerosis: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for re

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933.PUB2

7 January 2021

10.1002/14651858.CD008933.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

289147

289147

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference